Literature DB >> 20848232

Visfatin stimulates proliferation of MCF-7 human breast cancer cells.

Jae Geun Kim1, Eun Ok Kim, Bo Ra Jeong, Young Joo Min, Jeong Woo Park, Eun Sook Kim, Il Seong Namgoong, Young Il Kim, Byung Ju Lee.   

Abstract

Obesity, a condition characterized by increased fat content and altered secretion of adipokines, is a risk factor for postmenopausal breast cancer. Visfatin has recently been established as a novel adipokine that is highly enriched in visceral fat. Here we report that visfatin regulated proliferation of MCF-7 human breast cancer cells. Exogenous administration of recombinant visfatin increased cell proliferation and DNA synthesis rate in MCF-7 cells. Furthermore, visfatin activated G1-S phase cell cycle progression by upregulation of cyclin D1 and cdk2 expression. Visfatin also increased the expression of matrix metalloproteinases 2, matrix metalloproteinases 9, and vascular endothelial growth factor genes, suggesting that it may function in metastasis and angiogenesis of breast cancer. Taken together, these findings suggest that visfatin plays an important role in breast cancer progression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20848232     DOI: 10.1007/s10059-010-0124-x

Source DB:  PubMed          Journal:  Mol Cells        ISSN: 1016-8478            Impact factor:   5.034


  23 in total

1.  Effect of oncological treatment on serum adipocytokine levels in patients with stage II-III breast cancer.

Authors:  Teoman Coskun; Funda Kosova; Zeki Ari; Aslan Sakarya; Yavuz Kaya
Journal:  Mol Clin Oncol       Date:  2016-03-10

Review 2.  Nicotinamide phosphoribosyltransferase in malignancy: a review.

Authors:  Rodney E Shackelford; Kim Mayhall; Nicole M Maxwell; Emad Kandil; Domenico Coppola
Journal:  Genes Cancer       Date:  2013-11

3.  Resistin, visfatin, adiponectin, and leptin: risk of breast cancer in pre- and postmenopausal saudi females and their possible diagnostic and predictive implications as novel biomarkers.

Authors:  Adel M A Assiri; Hala F M Kamel; Mohamed F R Hassanien
Journal:  Dis Markers       Date:  2015-03-08       Impact factor: 3.434

4.  Visfatin Mediates SCLC Cells Migration across Brain Endothelial Cells through Upregulation of CCL2.

Authors:  Tingting Liu; Ziwei Miao; Jiusheng Jiang; Shuai Yuan; Wengang Fang; Bo Li; Yuhua Chen
Journal:  Int J Mol Sci       Date:  2015-05-18       Impact factor: 5.923

5.  Secretion of one adipokine Nampt/Visfatin suppresses the inflammatory stress-induced NF-κB activity and affects Nampt-dependent cell viability in Huh-7 cells.

Authors:  Yi-Ching Lin; Hui-Chung Wu; Chen-Chung Liao; Yi-Chih Chou; Shwu-Fen Pan; Chi-Ming Chiu
Journal:  Mediators Inflamm       Date:  2015-02-26       Impact factor: 4.711

6.  Relationship between NAMPT/PBEF/visfatin and prognosis of patients with malignant tumors: a systematic review and meta-analysis.

Authors:  Chengjian Ji; Rong Cong; Yi Wang; Yamin Wang; Qijie Zhang; Xiang Zhou; Qianwei Xing; Ninghong Song
Journal:  Ann Transl Med       Date:  2019-12

7.  Diet-induced obesity potentiates the growth of gastric cancer in mice.

Authors:  Hai-Jun Li; Xiang-Ming Che; Wei Zhao; Shi-Cai He; Zheng-Liang Zhang; Rui Chen
Journal:  Exp Ther Med       Date:  2012-08-07       Impact factor: 2.447

8.  Regulative Effect of Nampt on Tumor Progression and Cell Viability in Human Colorectal Cancer.

Authors:  Xiaoqun Lv; Lingyun Zhang; Yanyan Zhu; Harun M Said; Jimin Shi; Guoxiong Xu
Journal:  J Cancer       Date:  2015-07-16       Impact factor: 4.207

9.  Changes in subcellular localization of visfatin in human colorectal HCT-116 carcinoma cell line after cytochalasin B treatment.

Authors:  R J Bułdak; M Skonieczna; Ł Bułdak; N Matysiak; Ł Mielańczyk; G Wyrobiec; M Kukla; M Michalski; K Żwirska-Korczala
Journal:  Eur J Histochem       Date:  2014-09-12       Impact factor: 3.188

10.  Visfatin promotes cell and tumor growth by upregulating Notch1 in breast cancer.

Authors:  Hyun-Joo Park; Su-Ryun Kim; Su Seong Kim; Hee-Jun Wee; Moon-Kyoung Bae; Mi Heon Ryu; Soo-Kyung Bae
Journal:  Oncotarget       Date:  2014-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.